

This listing of claims will replace all prior versions, and listing, of claims in the application:

Listing of the Claims:

What is claimed is:

1-9. (Cancelled).

10. (Currently Amended) An antiparallel triplex, comprising: (a) a first oligonucleotide strand comprising at least one 8-aminopurine; (b) a linker connected to said first strand; (c) a second oligonucleotide strand connected to the opposite end of said linker from the first oligonucleotide strand and capable of forming a hairpin with said first oligonucleotide strand; and (d) a third oligonucleotide strand comprising pyrimidines, wherein said third oligonucleotide strand is substantially complementary to and antiparallel to said first oligonucleotide strand, and wherein said antiparallel triplex is selected from the group consisting of (i) a triplex formed from three oligonucleotides, wherein a first oligonucleotide comprises SEQ ID NO: 6, a second oligonucleotide comprises SEQ ID NO: 7, and a third oligonucleotide comprises SEQ ID NO: 8; and (ii) a triplex formed from three oligonucleotides, wherein a first oligonucleotide comprises SEQ ID NO: 6, a second oligonucleotide comprises SEQ ID NO: 7, and a third oligonucleotide comprises SEQ ID NO: 9.

11. (Original) The triplex of claim 10, wherein said second oligonucleotide is bound to said first oligonucleotide in one of a Hoogsteen configuration or a reverse Hoogsteen configuration.

12-13. (Cancelled).

14. (New) The triplex of claim 10, wherein one or more of the purines in the triplex is replaced by an 8-aminopurine.

15. (New) The triplex of claim 14, wherein said 8-aminpurine is selected from the group consisting of 8-aminoadenine, 8-aminoguanine, and 8-aminohypoxanthine.